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Background: FLT3-ITD and FLT3-TKD mutations are frequently found in acute myeloid leukemia (AML). This makes
tyrosine kinase FLT3 a highly attractive target for therapeutic drug development. However, effective drugs have not
yet emerged. This study is intended to identify and to characterize new FLT3 inhibitors.
Methods: By using the protein substrate GST-FLT3S to analyze kinase activity of recombinant proteins carrying the
catalytic domain of wild type and mutant forms of FLT3, we screened a chemical library containing 80 known
protein kinase inhibitors. We identified SU11652 as a potent FLT3 inhibitor and further employed FLT3-ITD-positive
MV- 4–11 cells to study its effects on cell growth, apoptosis, cell cycles, and cell signaling.
Results: SU11652 strongly inhibited the activity of wild type, D835Y, and D835H mutant forms of FLT3 with IC50
values of 1.5, 16, and 32 nM, respectively. It effectively blocked the growth of FLT3-ITD -positive MV-4-11 cells at
nanomolar concentrations but exhibited much less effects on several other cells which do not carry mutations of
FLT3. SU11652 inhibited growth of MV-4-11 cells by inducing apoptosis, causing cell cycle arrest, and blocking
activation of the ERK, Akt, and STAT signaling pathways.
Conclusion: SU11652 is a potent FLT3 inhibitor which selectively targets FLT3-ITD-positive cells. It should serve as a
good candidate for development of therapeutic drugs to treat AML.
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Acute myeloid leukemia (AML) is the most common
malignant myeloid disorder in adults and is featured by
abnormal differentiation and proliferation of hematopoi-
etic progenitor cells of the myeloid lineage [1]. The me-
dian age of AML patients at diagnosis is 67 years, and it
is estimated that 13,780 (7,350 men and 6,430 women)
will be diagnosed with and 10,200 will die of the disease
in 2012 in USA [2]. Currently, there is no effective cure
for the disease. With standard chemotherapy, the 3-year
event-free survival rate of patients with favorable cy-
togenetics is 60%; however, the median survival of pa-
tients with unfavorable cytogenetics is only 6 months
[1,3]. Therefore, novel therapies with higher efficacy and* Correspondence: fxq@jlu.edu.cn; Joe-zhao@ouhsc.edu
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reproduction in any medium, provided the orfewer side effects are badly needed. With the increa-
sed understanding of the pathogenesis of AML, several
molecular lesions have been identified, which allows de-
velopment of targeted drugs [4]. Among them, FMS-like
tyrosine kinase 3 (FLT3) is one of the most attractive
targets, and related drug therapies are currently under
development [5,6].
FLT3 is a receptor tyrosine kinase mainly expressed in
early myeloid and lymphoid progenitors, and it plays a
role in the development of hematopoietic progenitor
cells [7]. Mutations of FLT3 have been found in about
30% of AML patients [8]. Among these mutations, the
most common type is FLT3-ITD caused by internal tan-
dem duplication (ITD) in the juxtamembrane domain,
and the less common FLT3-TKD type involves point
mutations in the tyrosine kinase domain (TKD). These
mutations lead to constitutive activation of FLT3 and re-
sult in uncontrolled proliferation of leukemia cells [9],
and they are strongly associated with poor prognosis in
AML patients [10]. Since mutations found in AML. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 SU11652 is a potent FLT3 inhibitor. A. Tyrosine kinase
activity of recombinant FLT3, FLT3D835H, and FLT3 D835Y was
analyzed with GST-FLT3S as the substrate in the presence of various
concentrations of SU11652. Tyrosine phosphorylation of GST-FLT3S
was detected by using anti-phosphotyrosine antibody PY20, and its
protein level, by Coomassie blue staining. B. The relative kinase
activity was calculated based on the density of the western blot
bands normalized to the control group. Error bars denote standard
deviation (n = 3).
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target for anticancer drugs. Up to date, several small
molecule inhibitors and monoclonal antibodies against
FLT3 have been developed [11-14]. Clinical trials have
shown the efficacy of some FLT3 inhibitors in treatment
of AML, but the responses are incomplete and often
limited by the acquired resistance during the treatment
[15-17]. For off-label use, sorafenib, which was initial-
ly identified as an inhibitor of VEGFR/PDGFR tyrosine
kinases and Raf kinases, is the only FDA-approved anti-
cancer drug targeting FLT3 [18]. Needless to say, identi-
fication of novel FLT3 inhibitors with higher potency
is required.
In this study, by screening a protein kinase inhibitor li-
brary using a protein substrate we recently developed
[19], we identified SU11652 as a potent FLT3 inhibitor.
We further performed cell-based assays to demonstrate its
inhibitory selectivity and potency for FLT3-ITD-positive
cells and the cellular and molecular mechanism under-
lying its action. We believe that SU11652 should serve as
a good candidate for development of targeted drugs to
treat AML.
Results and discussion
SU11652 is a potent FLT3 inhibitor
In our previous studies, we developed a system to ana-
lyze kinase activity of FLT3 by using a protein substrate
[19]. We now employed the assays to screen chemical
libraries for identification of FLT3 inhibitors. The libra-
ry that we chose for this study is the InhibitorSelect™
96-Well Protein Kinase Inhibitor Library I from Calbio-
chem. The library consists of 80 cell-permeable protein
kinase inhibitors. The compounds were supplied at a
concentration of 10 mM in dimethyl sulfoxide (DMSO).
Our initial screening was performed with 3 μM and then
0.3 μM of each inhibitor. This led to identification of
several compounds that exhibited strong inhibitory ef-
fects on FLT3 and its FLT3D835Y and FLT3 D835H
mutant forms (data not shown). One of the compounds,
SU11652, was further characterized. Figure 1 shows the
dose responses. SU11652 inhibited the kinase activity of
wild type FLT3 with an IC50 value of ~1.5 nM. It dis-
played relatively lower potency toward the FLT3D835Y
and FLT3D835H mutants with IC50 values of 16 and 32
nM, respectively. SU11652 is a sunitinib-like oxindole
inhibitor and has been found as an inhibitor of PDGFRβ,
VEGFR2, FGFR1, Flk-1, and cKit with IC50 or Ki values
of 3–500 nM [20,21]. Our study now suggests that it
inhibits FLT3 with even higher potency. It is interesting
to note that the D835Y and D835H mutant forms of
FLT3 are less sensitive to SU11652 than the wild type
FLT3. This is reminiscent of data obtained with two other
known FLT3 inhibitors, namely, sorafenib and AC220
(quizartinib) [15]. On the other hand, FLT3-ITD mutantscontain the wild type kinase domain and should be high-
ly sensitive to inhibition by SU11652. Therefore, in the
clinical applications, SU11652 would be more suitable for
patients with FLT3-ITD mutations than those with FLT3-
TDK mutations.
SU11652 inhibits the growth of FLT3-ITD-positive cells
We further employed cell-based assays to verify the in-
hibitory effects of SU11652 on FLT3. For this purpose,
the MV-4-11 cell line was employed. The cells were
derived from biphenotypic B myelomonocytic leukemia
and carry a FLT3-ITD mutation [22]. As expected, MTT
assays revealed that MV-4-11 cells were highly sensitive
to SU11652 with an IC50 value of ~5 nM (Figure 2A). In
contrast, HL-60 acute promyelocytic leukemia, Jurkat
acute T cell leukemia cells, and Karpas 299 anaplastic
large cell lymphoma cells were hardly affected by the in-
hibitor at 500 nM. These cells do not carry FLT3 mu-
tations. The data demonstrate that SU11652 specifically
targets cells containing FLT3-ITD. It should be noted
that Karpas 299 cells contain a mutation of tyrosine kinase
Figure 2 SU11652 effectively inhibits the growth of MV-4-11 cells. A. MV-4-11, HL-60, Karpas 299, and Jurkat cells were cultured in the
presence of various concentrations of SU11652 for 48 hours. Cell viability was assessed by MTT assays. Error bars denote standard deviation
(n = 3). B. Wright-Giemsa staining of MV-4-11 and HL-60 cells treated with 0 or 100 nM SU11652 for 48 h. Black arrows point to mitotic cells.
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selective for tyrosine kinases mutated in cancer cells. The
inhibitory effects of SU11652 on the growth of MV-4-11
cells were also demonstrated by Wright-Giemsa staining
of cells fixed to glass slides by cytospin. As shown in
Figure 2B, in comparison with the non-treated MV-4-11
cells, cells treated with 100 nM SU11652 were sparser and
smaller, showing no mitotic cells but rather condensed
nuclei and cell debris. As a control, HL-60 cells behaved
normally showing regular morphology and many mitotic
cells in the presence of 100 nM SU11652.Figure 3 SU11652 induces apoptosis of MV-4-11 cells. MV-4-11 cells w
stained with Cy5-labeled annexin V and propidium iodide, followed by ana
propidium iodide-negative cells, that is, apoptotic cells, are indicated.SU11652 induces apoptosis and cell cycle arrest in
MV-4-11 cells
To reveal further how SU11652 inhibits the growth of
MV-4–11 cells, we conducted apoptosis assays and cell
cycle analyses. Apoptosis was demonstrated by staining
with Annexin V and propidium iodide. As shown in
Figure 3, the percentage of Annexin V-positive and pro-
pidium iodide-negative cells was increased following
SU11652 treatment, reaching 17.7% at 100 nM, indicating
induction of apoptotic cell death. The effects of SU11652
on the cell cycle were even more prominent. As shownere incubated with 0, 10 and 100 nM SU11652 for 24 hours. Cells were
lyses with a flow cytometry. Percentages of annexin V-positive and
Figure 4 SU11652 induces cell cycle arrest of MV-4-11 cells. MV-4-11 cells were incubated with 0, 10, and 100 nM SU11652 for 24 hours.
Cells were fixed with ethanol and stained with propidium iodide before flow cytometric analysis. Percentages of cells in G1, S, and G2 phases
were calculated by using the ModFit software.
Figure 5 SU11652 blocks activation of signal transduction
pathways downstream of FLT3. MV-4-11 cells were treated with
the indicated concentrations of SU11652 for 24 hours. Cell extracts
were subjected to western blot analyses with antibodies against
phosphorylated forms of FLT3 (pY591), ERK1/2 (pT202/pY204), Akt
(pS473), and STAT5 (pY694). Equal protein loading was demonstrated
by blotting with house-keeping gene product GAPDH.
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SU11652 reduced S phase cells from 24.7% to 7.6%,
accompanied by comparable reduction in the percen-
tages of G2 phase cells. Together, the data indicate that
SU11652 induces both apoptosis and cell cycle arrest of
MV-4-11 cells.
SU11652 inhibits FLT3 downstream signaling in
MV-4-11 cells
As a growth factor receptor, FLT3 turns on various sig-
naling pathways to regulate cell growth and proliferation
[9]. These include the Ras/MAPK, PI3K/Akt, and JAK/
STAT pathways. Mutations of FLT3 are known to cause
constitutive activation of FLT3 kinase activity and down-
stream signaling components [9]. To see if the inhibi-
tion of FLT3 kinase activity by SU11652 also blocks its
downstream signal transduction events, we used phospho-
specific antibodies to detect activation of ERK1/2, Akt,
and STAT5 in MV-4-11 cells. Figure 5 shows a dose-
dependent reduction in the phosphorylation levels of
FLT3, ERK1/2, Akt, and STAT5 in MV-4-11 cells treated
with SU11652. This indicates that the activation of these
downstream signaling proteins in MV-4–11 is blocked by
SU11652, thereby providing a molecular mechanism for
the inhibition of cell growth by the inhibitor.
Conclusions
By screening a chemical library with an effective FLT3
kinase assay system, we have identified SU11652 as a
potent inhibitor of FLT3 with an IC50 value of 1.5 nM.
More importantly, our in vitro cell-based assays demon-
strated that SU11652 selectively inhibited the growth
of FLT3-ITD-positive MV-4-11cells with equivalent po-
tency. Furthermore, we showed that SU11652 induced
apoptosis, caused cell cycle arrest, and blocked FLT3
downstream signaling transduction. FLT3 is an obvious
target for therapeutic drugs to AML, but no effective drug
has emerged. Our study provides a new candidate. Con-
sidering the potency and selectivity of SU11652 according
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study with animal models and clinical studies with FLT3-
ITD -positive AML patients appears to be well warranted.
Methods
Materials
InhibitorSelect Protein Kinase Library I containing 80
protein kinase inhibitors including SU11652 was pur-
chased from Calbiochem (CA, USA). Monoclonal anti-
phosphotyrosine antibody PY20 was from BD Biosciences
(CA, USA), while antibodies against pFLT3 (pY591),
pERK1/2(pT202/pY204), pAKT(pS473), and pSTAT5
(pY694) were from Cell Signaling Technology (MA, USA).
MV-4–11, HL-60, and Jurkat cell lines were obtained from
ATCC (VA, USA). Karpas 299 cells were kindly provided
by Yi Zhao (University of Southern California, [23]). MV-
4-11 cells were cultured in Iscove’s Modified Dulbecco’s
Medium containing 10% fetal bovine serum, and the rest
of cells were maintained in RPMI medium supplemented
with 10% fetal bovine serum.
FLT3 kinase activity assays and inhibitor screening
Protein kinase activity assays and inhibitor screening
were performed as previously described [19,25]. The FLT3
substrate GST fusion protein GST-FLT3S was purified
from E. coli cells by using a glutathione-Sepharose co-
lumn, and recombinant proteins containing the catalytic
domain of wild type FLT3 and its D835H and D835Y mu-
tant forms were isolated from recombinant baculovirus-
infected Sf9 insect cells by using the NTA-Ni resin [19].
Phosphorylation of GST-FLT3S by isolated FLT3 tyrosine
kinases was carried out in a reaction buffer containing
25 mM Tris–HCl (pH 7.5), 10 mM MgCl2, 0.2 mM
adenosine 50-triphosphate, and 2 mM dithiothreitol in
the presence of various concentrations of protein kinase
inhibitors. The level of GST-FLT3S tyrosine phospho-
rylation was determined by immunoblotting with anti-
phosphotyrosine antibody PY20 followed by horseradish
peroxidase-conjugated secondary antibody. Detection and
quantification of enhanced chemiluminescence signals
were done by using FluorChem SP imaging system from
Alpha Innotech [26].
Cell viability assays
MV-4-11, HL-60, Karpas 299, and Jurkat cells were
incubated with various concentrations of SU11652 for
48 hours. To measure the viability of cells, 0.5 mg/ml
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) was added into the medium. After incuba-
tion at 37°C for 3 hours, the medium was removed by
centrifugation and the precipitated dye was dissolved in
1 ml isopropanol containing 0.04 M HCl. Absorbance at
570 nm was then measured with a spectrophotometer.Apoptosis and cell cycle analyses
For apoptosis analysis, the cells were stained with Annexin
V-Cy5 and propidium iodide (Biovision, CA, USA). To as-
sess cell cycle arrest, the cells were fixed with ethanol
overnight and then stained with propidium iodide in the
presence of RNAse. Flow cytometric assays were per-
formed by using a FACSCalibur flow cytometer (BD Bio-
sciences) at the Flow and Image Cytometry Laboratory of
University of Oklahoma Health Sciences Center.
Cell signaling assays
Cells treated with SU11652 or the control solvent were
extracted with a whole-cell extraction buffer containing
25 mM β-glycerophosphate (pH 7.3), 5 mM EDTA,
2 mM EGTA, 5 mM β-mercaptoethanol, 1% Triton
X-100, 0.1 M NaCl, 1 mM sodium vanadate, and a protea-
se inhibitor cocktail (Roche Applied Science, Indianapolis,
IN, USA). Cell lysates were cleared by centrifugation in a
microfuge at 13,000 g, and clear cell extracts containing
equal amounts of total proteins were separated on SDS
gels for western blot analyses with antibodies against
pFLT3, pERK, pAKT, and pSTAT5.
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